AdipoSeeds raises equity from Sysmex and Daiwa biotech fund
The financing supports preparations for clinical studies of platelet-like cells for hard-to-heal skin ulcers and transfusion applications.
AdipoSeeds announced equity financing from Sysmex Corporation and Daiwa Taiwan-Japan BioVenture Investment Limited Partnership II on January 9, 2026. The company did not disclose the amount or name a funding stage.
The funds were intended to support preparations for a domestic phase I/II study of ADS-01 for hard-to-heal skin ulcers, and an exploratory clinical study of ADS-02 for platelet transfusion. At the announcement, the latter study’s regenerative-medicine provision plan had completed committee review at the Institute of Science Tokyo.
AdipoSeeds and Sysmex were also exploring collaboration on quality control and manufacturing. The partnership would combine AdipoSeeds’ regenerative-medicine development expertise with Sysmex’s testing assets, cell-manufacturing knowledge and network, with the aim of improving production quality and reducing manual work.
Use of funds
Prepare domestic phase I/II study of ADS-01 for hard-to-heal skin ulcers
Begin exploratory clinical research on ADS-02 for platelet transfusion